147 related articles for article (PubMed ID: 34648871)
1. Stereotactic body radiotherapy for head and neck skin cancer.
Voruganti IS; Poon I; Husain ZA; Bayley A; Barnes EA; Zhang L; Chin L; Erler D; Higgins K; Enepekides D; Eskander A; Karam I
Radiother Oncol; 2021 Dec; 165():1-7. PubMed ID: 34648871
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy for distant metastases to the head and neck.
Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
[TBL] [Abstract][Full Text] [Related]
3. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
Rwigema JC; Heron DE; Ferris RL; Andrade RS; Gibson MK; Yang Y; Ozhasoglu C; Argiris AE; Grandis JR; Burton SA
Am J Clin Oncol; 2011 Aug; 34(4):372-9. PubMed ID: 20859194
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy for medically unfit patients with cancers to the head and neck.
Al-Assaf H; Erler D; Karam I; Lee JW; Higgins K; Enepekides D; Zhang L; Eskander A; Poon I
Head Neck; 2020 Aug; 42(8):2050-2057. PubMed ID: 32199031
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy as primary treatment for elderly and medically inoperable patients with head and neck cancer.
Gogineni E; Rana Z; Vempati P; Karten J; Sharma A; Taylor P; Pereira L; Frank D; Paul D; Seetharamu N; Ghaly M
Head Neck; 2020 Oct; 42(10):2880-2886. PubMed ID: 32691496
[TBL] [Abstract][Full Text] [Related]
7. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
8. Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?
Nagpal SK; Khabra K; Ross G; Kirby AM
Clin Oncol (R Coll Radiol); 2023 Nov; 35(11):736-743. PubMed ID: 37684189
[TBL] [Abstract][Full Text] [Related]
9. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
10. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials.
Pezzulla D; Macchia G; Cilla S; Buwenge M; Ferro M; Bonome P; Romano C; Zamagni A; Valentini V; Morganti AG; Deodato F
Clin Exp Metastasis; 2021 Dec; 38(6):519-526. PubMed ID: 34651242
[TBL] [Abstract][Full Text] [Related]
12. Two-institution results of Stereotactic Body Radiation Therapy (SBRT) for treating adrenal gland metastases from liver cancer.
Xu B; Zhao X; Chen D; Zhao W; Wang X; Ding C; Yuan Z; Zhang H
BMC Cancer; 2023 Jan; 23(1):73. PubMed ID: 36681809
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
Singh R; Ansinelli H; Sharma D; Jenkins J; Davis J; Vargo JA; Sharma S
Am J Clin Oncol; 2019 Jul; 42(7):602-606. PubMed ID: 31232723
[TBL] [Abstract][Full Text] [Related]
14. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Aghdam N; Lischalk JW; Marin MP; Hall C; O'Connor T; Campbell L; Suy S; Collins SP; Margolis M; Krochmal R; Anderson E; Collins BT
Front Oncol; 2021; 11():728519. PubMed ID: 34912703
[TBL] [Abstract][Full Text] [Related]
15. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience.
Akbaba S; Heusel A; Mock A; Held T; Lang K; Hoerner-Rieber J; Forster T; Katayama S; Kargus S; Rieken S; Plinkert P; Herfarth K; Debus J; Adeberg S
Oral Oncol; 2019 Oct; 97():115-123. PubMed ID: 31494395
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome and toxicity of hypofractionated stereotactic body radiotherapy as a boost treatment for head and neck cancer: the importance of boost volume assessment.
Lee DS; Kim YS; Cheon JS; Song JH; Son SH; Jang JS; Kang YN; Kang JH; Jung SL; Yoo IeR; Jang HS
Radiat Oncol; 2012 Jun; 7():85. PubMed ID: 22691266
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
Kalash R; Glaser SM; Flickinger JC; Burton S; Heron DE; Gerszten PC; Engh JA; Amankulor NM; Vargo JA
J Neurosurg Spine; 2018 Aug; 29(2):220-225. PubMed ID: 29799334
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
[TBL] [Abstract][Full Text] [Related]
19. Single community-based institutional series of stereotactic body radiation therapy (SBRT) for treatment of liver metastases.
Anstadt EJ; Shumway R; Colasanto J; Grew D
J Gastrointest Oncol; 2019 Apr; 10(2):330-338. PubMed ID: 31032102
[TBL] [Abstract][Full Text] [Related]
20. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
